Genes, Vol. 15, Pages 567: Distribution of BCR::ABL1 Transcripts in the Different Clinical Phases of Chronic Myeloid Leukemia: Effect on Hematological Parameters and Patient Survival
This study therefore aimed to determine the distribution of BCR::ABL1 mRNA variants in different clinical phases of CML and their effect on hematological parameters and patient survival. This study included 33 patients, whose demographic, clinical, and molecular data on BCR::ABL1 mRNA variants and hematological parameters were collected to identify potential associations. A total of 84.8% (n = 28) of patients had BCR::ABL1 translocation and increased platelet and basophil counts. The most frequent mRNA variant was b3a2 (64.3%), followed by b2a2 (28.6%) and e1a2 (3.6%). Concerning the clinical phases of CML, 75.8% (n = 25), 21.2% (n = 7), and 3% (n = 1) of patients were in the chronic, blast, and accelerated phases, respectively. Moreover, the b3a2 mRNA variant was more commonly identified in patients in the chronic phase. No correlation was observed between mRNA variant expression and patient survival. However, b2a2 was indicative of patients with longer survival as well as those treated with imatinib or nilotinib. Additionally, platelet count could be a marker of BCR::ABL1 translocation.
Source: Genes - Category: Genetics & Stem Cells Authors: Pablo Romero-Morelos Ana Lilia Gonz ález-Yebra Anaid Herrer ías-García Francisco Arath Ru íz-Velázquez Luis Jonathan Bueno-Rosario Beatr íz González-Yebra Tags: Article Source Type: research
More News: Chronic Leukemia | Chronic Myeloid Leukaemia | Genetics | Gleevec | Hematology | Leukemia | Mexico Health | Nilotinib | Stem Cell Therapy | Stem Cells | Study | Tasigna | Translocation